Suresh Durgam, MD

Former employee of Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, New Jersey

  • 11Articles
  • 91.7KReads
  • 2014–2026Active
  • 39Collaborators
  • 470Citations

About

Suresh Durgam, MD, is affiliated with Intra-Cellular Therapies, A Johnson & Johnson company, in Bedminster, New Jersey. His publications from 2014 to 2026 focus on clinical research involving major depressive disorder, schizophrenia and schizoaffective disorders, anxiety, bipolar disorder, anxiolytics, and sexual dysfunction. He has contributed to studies evaluating the efficacy and safety of pharmacologic treatments such as lumateperone, vilazodone, and cariprazine across these psychiatric conditions. His work often includes randomized, double-blind clinical trials and post hoc analyses.

Publications

JCP
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Original Research

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress

September 14, 2026

Adjunctive lumateperone 42 mg significantly improved depression and anxiety symptoms in patients with MDD with inadequate antidepressant response and anxious distress
, , , et al
JCP
Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder
Original Research

Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder

September 2, 2026

Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction.
, , , et al
JCP
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
Original Research

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

August 25, 2025

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
, , , et al
JCP
Efficacy of Lumateperone in Bipolar Depression With Mixed Features
Original Research

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

April 24, 2023

Lumateperone significantly improved depression symptoms, disease severity, and quality of life in patients with bipolar depression with mixed features.
, , , et al
JCP
NNT, NNH, and LHH for Lumateperone
Original Research

NNT, NNH, and LHH for Lumateperone

March 6, 2023

The benefit-risk assessment of lumateperone was favorable as measured by number-needed-to-treat and number-needed-to-harm analyses.
, , , et al
JCP
Original Research

Vilazodone in Generalized Anxiety Disorder

December 28, 2016

The worries that characterize generalized anxiety disorder are so pervasive and excessive that they distort cognition and create a considerable burden of illness. See what the authors of this...
, , , et al
PCC
Article

Vilazodone and Psychic and Somatic Anxiety

April 28, 2016

Is the SSRI vilazodone effective for treating generalized anxiety disorder? To comprehensively evaluate the effect of vilazodone across the range of anxiety symptoms associated with the disorder, Khan and...
, , , et al
JCP
Original Research

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder

March 23, 2016

, , , et al
JCP
Original Research

The Effect of Cariprazine on Hostility Associated With Schizophrenia: Post Hoc Analyses From 3 Randomized Controlled Trials

January 27, 2016

, , , et al
JCP
Original Research

Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial

December 23, 2015

, , , et al
JCP
Original Research

Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

November 25, 2014

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe